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Abstract
Background: The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients
with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy
options, oxaliplatin might be as effective as cisplatin but has shown to be more tolerable. To further improve
treatment options for patients with advanced gastric cancer, we initiated a study to evaluate the efficacy and safety
of trastuzumab plus oxaliplatin/capecitabine in patients with HER2-positive advanced gastric cancer.
Methods: CGOG1001 was an open-label, multicenter, prospective phase II study. Patients with chemotherapy-naive
HER2-positive advanced gastric cancer were eligible. Trastuzumab was administered at a loading dose of 8 mg/kg
followed by 6 mg/kg infusion every 3 weeks (q3w). Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for
up to 6 cycles. Capecitabine 1000 mg/m2 was given orally twice daily on days 1–14 followed by a 7-day rest
interval. Trastuzumab and capecitabine were continued until disease progression or intolerable toxicity. The primary
endpoint was objective response rate. Simon two-stage design (H0 = 40 %, H1 = 60 %, α = 0.05, β = 0.2) by Response
Evaluation Criteria In Solid Tumors 1.0 was applied.
Results: Fifty-one patients were enrolled. Confirmed response was recorded in 46 patients. One patient achieved
complete response and 33 patients achieved partial response (response rate 34/51 [66.7 %] in the intent-to-treat
population). Median follow-up time was 28.6 months, with a median progression-free survival of 9.2 months (95 %
confidence interval [CI]: 6.5–11.6) and a median overall survival (OS) of 19.5 months (95 % CI: 15.5–26.0). Patients with a
HER2/CEP17 ratio of greater than five achieved improved OS (20.9 vs 19.5 months, p = 0.001). The most common adverse
events of grade 3 or above were thrombocytopenia (21.6 %), neutropenia (13.7 %), anemia (5.9 %) and leucopenia (3.9 %).
Conclusion: The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated
encouraging efficacy.
Trial registration: ClinicalTrials.gov NCT01364493.
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Background
The ToGA trial was a phase III, open-label, randomized
controlled trial that established that patients with human
epidermal growth factor receptor 2 (HER2)-positive ad-
vanced gastric or gastroesophageal cancer who received
trastuzumab plus capecitabine (a fluoropyrimidine) and
cisplatin had better outcomes compared with patients who
received chemotherapy alone [1]. Median progression-free
survival (PFS) in the trastuzumab plus chemotherapy
group was 6.7 months compared with 5.5 months in the
chemotherapy-only group. Median overall survival (OS)
was also improved in the trastuzumab group (13.8 vs
11.1 months in the chemotherapy-only group). An
exploratory analysis of patients whose tumors had high
levels of HER2 protein demonstrated a median OS of
16 months for those treated with trastuzumab plus
chemotherapy versus 11.8 months for those treated with
chemotherapy alone.
In clinical practice, the use of cisplatin requires hydra-
tion, and impacts the kidney and gastrointestinal tract,
making tolerability particularly challenging for gastric
cancer patients. The REAL2 trial demonstrated that oxa-
liplatin has at least equivalent efficacy and is better toler-
ated than cisplatin in advanced gastric cancer [2]. A
meta-analysis of the ML17032 and REAL2 trials demon-
strated that capecitabine-based therapy had superior OS
benefits compared with 5-FU combinations in patients
with advanced gastroesophageal cancer [3, 4]. In the
ToGA trial, the majority of patients received capecitabine
rather than 5-FU [1]. Further, capecitabine is administered
orally and thus, more convenient than intravenous 5-FU.
According to resource-stratified guidelines for the man-
agement of gastric cancer from the Asian Oncology
Summit 2013, capecitabine/oxaliplatin is a preferred
first-line treatment for advanced gastric cancer in East-
ern Asian countries [5]. Jing et al. demonstrated that
adding trastuzumab to oxaliplatin increases antitumor
effect in vitro [6]. However, there are no established
positive results for this doublet regimen combined with
trastuzumab in advanced gastric cancer. Therefore, the
Chinese Gastrointestinal Oncology Group (CGOG) ini-
tiated this multicenter, phase II, prospective clinical trial
(CGOG1001) to evaluate the efficacy and safety of tras-
tuzumab plus oxaliplatin/capecitabine as first-line treat-
ment for HER2-positive advanced gastric cancer.
Methods
Patient eligibility
Patients with previously untreated, HER2-positive (immu-
nohistochemical [IHC] 2+/dual silver in situ hybridization
[DSISH]-positive, or IHC 3+, assessed by the central
laboratory in Fudan University Shanghai Cancer Center),
histologically confirmed adenocarcinoma of the stomach
or gastroesophageal junction with metastatic/irresectable
lesion(s) were eligible. Patients with measurable disease
according to the Response Evaluation Criteria In Solid
Tumors (RECIST) 1.0, age ≥18 years, Eastern Cooperative
Oncology Group (ECOG) score 0–2, and adequate organ
function of bone marrow, liver and kidney were included.
Enrolled patients had to be capable of taking oral medica-
tion and had to be fully recovered from any surgery (ex-
cluding diagnostic biopsy) performed within 4 weeks prior
to study entry. Patients were excluded if they had received
previous oxaliplatin or previous systemic therapy for ad-
vanced disease (except adjuvant/neoadjuvant chemother-
apy completed at least 6 months before enrollment).
Patients with heart failure, coronary artery disease or myo-
cardial infarction within the previous 6 months (baseline
left ventricular ejection fraction [LVEF] <50 % measured
by echocardiography), other previous malignancy within
5 years (except non-melanoma skin cancer) and brain
metastasis (known or suspected) were also excluded.
All patients completed an informed consent form prior
to study entry. The study was approved by the ethics
committees of 11 centers (details in the list of ethics
committees), and all procedures were in accordance with
the ethical standards of the responsible committee on
human experimentation (institutional and national) and
with the Helsinki Declaration of 1964 and later versions.
Treatment
Trastuzumab (Herceptin®, Shanghai Roche Pharmaceuticals
Limited) was administered at a loading dose of 8 mg/kg
followed by 6 mg/kg infusion every 3 weeks (q3w). Oxali-
platin (Eloxatin®, Sanofi Ltd.) was administrated as a
130 mg/m2 infusion, q3w, up to 6 cycles. Capecitabine
1000 mg/m2 (Xeloda®, Shanghai Roche Pharmaceuticals
Limited) was given orally twice daily on days 1–14 followed
by a 7-day rest period. Trastuzumab and capecitabine were
continued until disease progression or intolerable toxicity.
Dose adjustments of chemotherapy and trastuzumab ther-
apy interruption were allowed to manage toxicity. If LVEF
dropped by 10 points from baseline and to below 50 %,
trastuzumab was withheld and a repeat LVEF assessment
performed within approximately 3 weeks. If LVEF did not
improve or worsened, or if clinically significant congestive
heart failure developed, discontinuation of trastuzumab was
strongly considered, unless the benefits for the individual
patient were deemed to outweigh the risks.
Assessments
Tumor response was evaluated according to RECIST 1.0.
Baseline overall tumor assessments were made within
21 days prior to treatment start by a suitable reproducible
technique (either computed tomography [CT] or mag-
netic resonance imaging [MRI] scan) for all patients.
Follow-up tumor evaluations were performed at 6-weekly
intervals (±7 days) during the first year. The interval was
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extended to 12 weeks during subsequent years. CT or
MRI scans of chest, abdomen and pelvis were carried
out at baseline and included scans for metastatic le-
sions. If no lesions were visible in the chest, X-ray was
used instead of CT scan on subsequent visits. CT/MRI
was used on the abdomen and pelvis at baseline and
subsequent visits for all patients. If the patient reported
deteriorating symptoms, an assessment was scheduled
as soon as possible. Central review of the CT and MRI
results was done to ensure response rates were evalu-
ated accurately.
The National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0 was used to
evaluate the clinical safety of treatments in this study.
Subjects were assessed for adverse events at each clinic
visit and for 6 months after the last intake of study drug.
Ultrasound was performed every 12 weeks to evaluate
the cardiac function. If LVEF decreased ≥10 %, the ultra-
sound was repeated within 1 month.
Statistical analysis
CGOG1001 was an open-label, multicenter, prospective
phase II study. The primary endpoint was objective
response rate (ORR). Secondary endpoints included tol-
erability, PFS and OS. To limit the sample size for the
first stage and at the same time reduce the risk of the
non-responders in this trial, we chose Simon two-stage
design to evaluate the efficacy of this regimen [7].
Because of a single arm setting, it would be more accur-
ate to measure and compare ORR than PFS. The sample
size was determined as follow hypothesis, assuming H0 =
0.40 (null hypothesis) and H1 = 0.60 (alternative hypoth-
esis) with a significance level of 0.05 and a power of 80 %.
The result specified a sample size of 46 patients distrib-
uted in two stages. If seven or more confirmed partial
responses (PRs) were achieved after the first 16 patients,
recruitment was extended up to 46 patients. Assuming a
10 % drop-out rate, a total number of 51 patients were
required.
PFS was calculated from the first day of chemotherapy
until the date of progressive disease (PD) or date of
death, whichever occurred first. The censoring date was
the last date of follow-up or last tumor measurement.
OS was calculated from the date the patient gave in-
formed consent to date of death or date of last assess-
ment if date of death was unknown. Duration of
response (DOR) was defined as the interval between the
first confirmed objective response (complete response
[CR] or PR) and PD or the last follow-up assessment.
PFS, DOR and OS curves were generated using the
Kaplan–Meier method. The level of statistical significance
was set at P < 0.05. SPSS version 16.0 was used for all
analyses.
Results
Patient demographics and baseline characteristics
From June 2011 to August 2012, 362 patients from 13
centers were screened. Seventy-two patients were IHC 3
+ or IHC 2+/DSISH-positive and 51 patients were en-
rolled (intent-to-treat [ITT] population). The cut-off
date for data analysis was February 28, 2014. Figure 1
shows the reasons for ineligibility and the number of pa-
tients included in the analysis. One patient was excluded
because of lack of measurable disease according to
RECIST 1.0. The median age was 57 years (range 27–78).
Thirty-one patients (60.8 %) presented with liver metasta-
ses. Thirty-four patients (66.7 %) had intestinal-type dis-
ease based on Lauren classification [8]. Patients’ baseline
characteristics are shown in Table 1.
Efficacy
The median number of treatment cycles given was 8
(range 1–32, total 558 cycles) and the median follow-up
time was 28.6 months. Confirmed response was recorded
in 46 patients (one CR, 1.9 %; 33 PR, 64.7 %; 10 stable dis-
ease, 19.6 %; two PD, 3.9 %; Fig. 2) Two patients had no
response evaluation and two patients had early withdrawal
of treatment because of serious adverse events. One case
was lost to follow-up, 44 cases progressed and 32 cases
died by the end of this study. Median PFS was 9.2 months
(95 % confidence interval [CI]: 6.5–11.6; Fig. 3) and ex-
pected median OS was 19.5 months (95 % CI: 15.5–26.0).
DOR was 10.9 months (95 % CI: 8.2–12.6).
We did a further analysis to distinguish the group that
would potentially benefit more from trastuzumab plus
oxaliplatin/capecitabine. We found a statistically signifi-
cant correlation between HER2/CEP17 ratio and im-
proved OS. Median HER2/CEP17 ratio was 20 (range
2.01–50.0). Patients who had a HER2/CEP17 ratio of >5
experienced prolonged OS (20.9 versus 19.5 months;
P = 0.001, data not shown). Subgroup analyses by
age, ECOG score, primary disease location, extent of
disease, liver metastases and prior gastrectomy were
not associated with significant differences in survival.
Safety
The frequencies of hematological and non-hematological
adverse events are shown in Table 2. The most com-
monly reported adverse events (all grades) were leuco-
penia (66.7 %), neutropenia (64.7 %), thrombocytopenia
(56.9 %), nausea/vomiting (54.9 %) and hepatic dysfunc-
tion (45.1 %). The most common grade 3/4 hematological
toxicities were thrombocytopenia (21.6 %), neutropenia
(13.7 %), anemia (5.9 %) and leucopenia (3.9 %). Nausea/
vomiting (3.9 %), diarrhea (3.9 %), hand-foot syndrome
(3.9 %) and neurotoxicity (3.9 %) were common grade 3/4
non-hematological toxicities. Eight patients experienced
serious adverse events including septic shock, pulmonary
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tuberculosis, vomiting, upper gastrointestinal hemorrhage,
duodenal papillary lesion (not confirmed by pathology),
gastroesophageal anastomotic leak, thrombocytopenia and
pyloric obstruction. The duodenal papillary lesion was not
related to study treatment; therefore, treatment was
reintroduced after temporary interruption. Tubercu-
losis and anastomotic leak were potentially treatment-
related and treatment was suspended. Upper gastrointes-
tinal hemorrhage and pyloric obstruction may have been
due to PD. Vomiting and thrombocytopenia were poten-
tially related to chemotherapy, leading to early withdrawal
of treatment. One patient died of septic shock during the
second cycle of chemotherapy. The patient presented at
baseline with liver metastases, poor performance status,
hypoproteinemia and hypoglycemia.
Six patients experienced asymptomatic LVEF decrease
≥10 % from baseline; five of these had LVEF levels
greater than 60 % (three at Weeks 12, 24, and 36, and
two during the follow-up period). The sixth patient dis-
continued trastuzumab due to asymptomatic LVEF
below 50 % during Week 12. Trastuzumab was inter-
rupted temporarily in two patients due to arrhythmia
during the 13th cycle, but was well tolerated throughout
the remainder of the treatment course. No cardiac fail-
ure was reported.
The dose of oxaliplatin had to be reduced due to adverse
events in 12 patients: nine patients had hematological tox-
icity (mostly thrombocytopenia and neutropenia) and two
patients experienced non-hematological toxicities. The
majority of capecitabine dose reductions were due to non-
hematological toxicities (15 patients) while two were due
to hematological toxicities, namely anemia.
Discussion
Trastuzumab, an anti-HER2 receptor monoclonal anti-
body, has emerged as the first targeted drug to improve OS
when combined with chemotherapy in advanced HER2-
positive gastric cancer [1]. Based on the promising results
of the ToGA trial, new, cisplatin-free, less toxic, more con-
venient, trastuzumab-based first-line regimens are being
tested in phase II trials (NCT01359397, NCT01191697,
NCT01503983, NCT01228045, NCT01461057) [9]. The
results of this study are similar to a study by Ryu et al,
which showed that trastuzumab plus oxaliplatin/cape-
citabine had good efficacy as first-line chemotherapy in
HER2-positive advanced gastric cancer [10]. For the
ITT population, the ORR observed in our study was
66.7 %, median PFS was 9.2 months and the expected
median OS was 19.5 months; these promising results
are not inferior to the ToGA trial [1].
Fig. 1 Study flow diagram showing all patients screened for inclusion in the study and reasons for ineligibility
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Chemotherapy-related toxicities observed in our
study were similar to those observed in other clinical
trials [1, 2, 11], with thrombocytopenia (21.6 %) and
neutropenia (13.7 %) reported as most common grade
3/4 hematological toxicities. Although the most com-
mon non-hematological toxicities in our study were hep-
atic dysfunction and nausea/vomiting, most cases were
mild and reversible. Oxaliplatin-related thrombocytopenia
and hepatic dysfunction can be managed easily by dose
modification. Serious adverse events reported in this trial
were slightly higher than Ryu et al reported. The majority
of these events were not related to treatment. One patient
with poor performance status died of septic shock, which
highlights the importance of precautions and active sup-
portive care. The addition of trastuzumab had no impact
on chemotherapy tolerability. Although six patients expe-
rienced asymptomatic LVEF decrease ≥10 % from baseline
on regular surveillance, only one patient discontinued
trastuzumab due to LVEF below 50 %. Two patients
recovered from arrhythmia after temporary interruption
of trastuzumab. Regular monitoring of cardiac function
is a vital part of patient care during administration of
trastuzumab.
Although trastuzumab-based treatment represents the
standard of care for HER2-positive gastric cancer patients,
benefits from this regimen may not be as great in certain
subgroups of patients. Comprehensive analyses have been
conducted to identify patients who will benefit most from
anti-HER2 targeted therapy. Gomez-Martin et al. reported
the use of HER2 gene amplification level as a predictive
factor for response to trastuzumab-based treatment and
survival benefit [12]. In that study, 50 patients who had a
HER2/CEP17 ratio ≥4.45 survived for more than
12 months. Their median OS was significantly improved
compared with patients with a ratio ≤4.45 (median, 21.3
vs. 13.6 months; P = 0.005). We conducted an exploratory
analysis of HER2/CEP17 ratio to identify patients who
would are most likely to benefit from trastuzumab plus
oxaliplatin/capecitabine and found that patients with a
HER2/CEP17 ratio >5 achieved significantly improved OS
than those with HER2/CEP17 ratio ≤5 (20.9 versus
19.5 months; P = 0.001). The HER2 amplification level
should be considered a significantly predictive biomarker
for selecting patients who are most likely to benefit from
trastuzumab-based therapy.
At the time of diagnosis, 4–14 % of gastric cancer
patients had liver metastases [13–15] and long-term sur-
vival is usually hard to achieve in these patients. Li et al.
analyzed the survival of 162 Chinese gastric cancer
patients with liver metastases who underwent systemic
chemotherapy or local treatment [16]. The median OS
was 9.5 months. One- and 2-year survival rates were
28.4 and 4.3 %, respectively. Furthermore, in the sub-
group analysis of the ToGA trial, patients with visceral
(lung or liver) metastases benefitted less from trastuzu-
mab combined with chemotherapy than the overall
population [1]. The result of our study showed similar
median PFS (278 days) for patients who presented with
Table 1 Patients’ characteristics at baseline (N = 51)
Patients’ characteristics Median %









Gastroesophageal junction 18 35.3
Type of gastric cancer(assessed by central laboratory)
Intestinal type 34 66.7
Diffuse type 10 19.6
Mix type 7 13.7
HER2 status
IHC 3+ 38 74.5
IHC 2+,Dual SISH + 13 25.5





Well-moderately differentiated 24 47.1
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liver metastases. Therefore, it should be worthwhile to
explore the optimal regimen of trastuzumab combined
with chemotherapy in gastric cancer patients with syn-
chronous liver metastases. Recently, a randomized,
phase III trials (NCT01450696, BO27798) were initiated
upon request by the US Food and Drug Administration
to evaluate the efficacy of increased dose of trastuzumab
for patients with advanced gastric cancer with metastatic
disease with documented liver or lung involvement.
Maintenance therapy has shown more benefit com-
pared with discontinuation of chemotherapy in colorec-
tal cancer and lung cancer [17–19]. However, the
question remains as to whether this treatment strategy
can improve survival for advanced gastric cancer
patients. Oncologists’ preferred treatment strategy is to
prescribe sufficient chemotherapy to maintain response
until progression or intolerance. However, it is challen-
ging to continue combination chemotherapy with good
tolerance in clinical practice. Moreover, gastric cancer
patients who are diagnosed at the advanced stage gener-
ally have poor performance status [5]. In the ToGA trial,
trastuzumab was designed to be administered until PD
to maximize clinical benefit without negatively influencing
quality of life [1]. Based on the published preliminary re-
sults of a phase II trial that showed promising efficacy for
first-line paclitaxel plus capecitabine in gastric cancer [20],
and because of the convenient oral administration of cap-
ecitabine, we optimized the regimen in the current study
Fig. 2 Waterfall plot of overall response of the target lesions measured by RECIST 1.0
Table 2 Toxicity possibly, probably, or definitely attributable to chemotherapy (n = 51)
Adverse events Grade 1 Grade 2 Grade 3 Grade 4 Total
No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Hematological
Leucopenia 15 29.4 17 33.3 1 1.96 1 1.96 34 66.7
Neutropenia 13 25.5 13 25.5 5 9.8 2 3.9 33 64.7
Anemia 12 23.5 10 19.6 3 5.9 0 0 25 49.0
Thrombocytopenia 7 13.7 11 21.6 7 13.7 4 7.8 29 56.9
Non-hematological
Hepatic dysfunction 19 37.3 3 5.9 1 1.9 0 0 23 45.1
Nausea/vomiting 15 29.3 11 21.6 2 3.9 0 0 28 54.9
Neurotoxicity 12 23.5 3 5.9 2 3.9 0 0 17 13.7
Hand-food syndrome 12 23.5 5 9.8 2 3.9 0 0 19 37.3
Anorexia 8 15.7 0 0 1 1.9 0 0 9 17.6
Diarrhea 5 9.8 4 7.8 2 3.9 0 0 11 21.6
Infusion reaction 3 5.9 2 3.9 0 0 0 0 5 9.8
Fatigue 1 1.9 3 5.9 1 1.9 0 0 5 9.8
Arrhythmia 2 3.9 3 5.9 0 0 0 0 5 9.8
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to continue trastuzumab plus capecitabine until PD and
demonstrated greater improvement in PFS than that ob-
served in the ToGA trial. We reduced oxaliplatin explor-
ation with fewer grade 3-4 peripheral neuropathy events
(4 %) than reported by Ryu et al. (11 %). Therefore, further
exploration of this treatment model in advanced gastric
cancer patients is worthwhile. On the basis of the CLAS-
SIC trial [11], adjuvant chemotherapy with oxaliplatin/
capecitabine is recommended in patients with stage II-III
gastric cancer who underwent R0 resection. Our results
might provide rationale for further investigations of tras-
tuzumab plus chemotherapy as adjuvant treatment in
HER2-positive gastric cancer patients.
Conclusion
The addition of trastuzumab to oxaliplatin/capecitabine
for treatment-naive HER2-positive gastric cancer pa-
tients was well tolerated and the results demonstrated
Fig. 3 Kaplan–Meier curves for progression-free survival (a) and overall survival (b)
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encouraging efficacy. Further large-scale studies are re-
quired to determine survival benefit.
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